CD8A and neoplasm: Our studies revealed that combination therapy further inhibited the proportion of MDSCs in the spleen and blood and reprogrammed them into a more mature phenotype, ultimately leading to the promotion of the differentiation of Th1-dominant CD4+ T cells and enhancing CD8+ T-mediated tumor killing.